SELLAS Life SciencesSLS
NASDAQPharmaceuticals
No cached AI snapshot yet for SLS.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
13 employees179.58M shares outstandinglisted 2008-03-12dividend yield 19.66%
Next earnings ~May 5, 2026 · Ex-dividend Mar 24, 2011 · Dividend $0.24 quarterly
About SELLAS Life Sciences
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Latest News
Showing market-wide stock news
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
Warsh’s Fed expected to hike rates 25bp as dot plot takes center stage
USD/JPY Price Forecast: Retreats from 155.50 with Fed’s policy in focus
Equities: Fed focus and energy shock – Deutsche Bank
Related Stocksin Pharmaceuticals
Ready to see the live AI view on SLS?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing SLS side-by-side with live signals.